The Rhythm (ASX:RHY) share price is surging 5% higher today. Here's why.

The Rhythm Biosciences Ltd (ASX: RHY) share price has climbed 5% higher today following United States approval of a patent for ColoSTAT.

| More on:
surging asx share price represented by piggy bank with rocket attached to it

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is climbing today after the company was granted a United States patent for ColoSTAT. At the time of writing, the Rhythm share price is up 5% to 84 cents.

Rhythm develops and commercialises Australian medical diagnostics technology for sale in domestic and international markets. The company's ColoSTAT is the first proposed product-in-development, intended to accurately test and detect the early stages of colorectal cancer.

New patent approval

In today's release, Rhythm advised the US Patents and Trademarks Office (USPTO) has approved a patent for ColoSTAT biomarkers. The new grant covers 3 core biomarkers that form part of the ColoSTAT blood test. Additional biomarkers can be added to the core markers, if required.

In highlighting the positive announcement, the company noted that USPTO approved less than 35% of diagnostics patent applications.

Addressable market

Rhythm believes the authorised patent will strengthen its growth profile in the US. The current screening for people aged 50 to 74 years old is estimated to be around 94 million. And it could grow by a further 21% following the US Preventative Services Task Force's recommendation to reduce the screening age to 45 years of age.

Nonetheless, this puts the company's world-wide access close to 800 million people, when including other approved markets such as Australia, China, Japan, the United Kingdom and Europe.

CEO commentary

Rhythm CEO Glenn Gilbert welcomed the patent approval, saying:

The granting of this US patent further strengthens Rhythm's global position as an emerging leader in the diagnosis of cancer, initially in the area of colorectal cancer.

The significance of this patent cannot be overstated, as it expands our access to a growing global market, and importantly, with ColoSTAT being a simple, low-cost option, means that we are in a position to access the mass market opportunity in each key country.

Having patent coverage in all the major global markets is a significant value-add for the Company.

Rhythm share price performance

The Rhythm share price has soared more than 500% higher in the past 12 months, reflecting the company's aggressive expansion into new geographical markets.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Animation of a man measuring a percentage sign, symbolising rising interest rates.
Share Market News

Are interest rate cuts now off the table for 2024?

The RBA is struggling in its battle with inflation. What does this mean for interest rates?

Read more »

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

These ASX 300 shares could rise 20% to 65%

Big returns could be on the cards for these shares according to analysts.

Read more »

Woman at home saving money in a piggybank and smiling.
Opinions

Why I just invested another $1,000 in my favourite ASX 200 stock

I’m planning to hold this stock for a very long time.

Read more »

A man looking at his laptop and thinking.
Share Market News

Why is the ASX 200 pumping the brakes before the weekend?

Australian investors don't have the appetite today, here's why.

Read more »

Miner and company person analysing results of a mining company.
Resources Shares

Buy one, sell the other: Goldman's verdict on these 2 ASX 200 mining shares

The broker sees significant valuation differences between these 2 major ASX 200 mining shares.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

a man weraing a suit sits nervously at his laptop computer biting into his clenched hand with nerves, and perhaps fear.
Share Fallers

Why BHP, Lynas, Metals X, and Super Retail shares are dropping today

These shares are ending the week in the red.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Latin Resources, Newmont, Nick Scali, and ResMed shares are surging today

These ASX shares are ending the week strongly. But why?

Read more »